Clinical Study

Fibroblast Growth Factor and Mineral Metabolism Parameters among Prevalent Kidney Transplant Patients

Madhumathi Rao, Priyanka Jain, Temitope Ojo, Gautam Surya, and Vaidyanathapuram Balakrishnan

Division of Nephrology, Tufts Medical Center, P.O. Box 391, 800 Washington Street, Boston, MA 02111, USA

Correspondence should be addressed to Madhumathi Rao, mrao@tuftsmedicalcenter.org

Received 5 March 2012; Accepted 23 April 2012

Academic Editor: Jaime Uribarri

Copyright © 2012 Madhumathi Rao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Chronic kidney disease (CKD) related mineral bone disorders persist after kidney transplantation, but little is known about the relationship between fibroblast growth factor-23 (FGF-23) and mineral metabolism in prevalent post-transplant patients. Objectives. To examine mineral metabolism parameters and their relationship to FGF-23 and parathyroid hormone (PTH) in prevalent kidney transplant patients. Methods. Cross-sectional study of 106 kidney transplant patients enrolled November 2005–October 2009 at Tufts Medical Center (TMC), Boston. Results. The prevalence of hypophosphatemia was 34%, hypercalcemia 3%, and elevated PTH levels 66%, at a median (25th–75th percentile) duration of 12.8 (7.5–30.9) months post-transplant. Males had significantly higher levels of PTH (P=0.04) and lower levels of serum phosphate (P=0.002). Serum PTH levels did not relate to eGFR, corrected calcium levels or serum phosphate. FGF-23 levels were above the reference limits in 7% of patients; higher levels were associated with higher serum phosphate and PTH levels after adjustment for transplant kidney function. Conclusion. FGF-23 is an important driver of mineral metabolism in prevalent transplant patients. Its modulatory role in mineral metabolism homeostasis may be heightened as feedback suppression of PTH is disturbed. Its role in long term cardiovascular and graft outcomes needs further study.

1. Introduction

Despite undergoing successful kidney transplantation, patients with chronic kidney disease (CKD) continue to have abnormalities in mineral metabolism. Persistent elevation of parathyroid hormone (PTH), sometimes autonomous, is well described, and hypophosphatemia owing to inappropriate urinary phosphate wasting with restoration of renal clearance is frequently seen in the early posttransplant period [1]. However, recent research also points to persistent posttransplant elevations of fibroblast growth factor-23 (FGF-23) as playing a major role in posttransplant hypophosphatemia and suppression of 1α-hydroxylase activity in the kidney [2, 3].

Although FGF-23 levels are reported to decline rapidly after transplant, there is limited information regarding its relationship to mineral metabolism in prevalent kidney transplant recipients. Kidney function is typically reduced in the transplant setting [4, 5], and the effects of transplant CKD on FGF-23 and mineral metabolism in the longer term are not well described. We report the results of a cross-sectional study where we examined abnormalities in mineral metabolism and their relationship to FGF-23 and PTH levels in prevalent transplant patients. As most studies have mainly addressed only the immediate changes following transplantation, this study represents an expansion in our understanding of the long-term effects of FGF-23 on mineral metabolism after transplantation.

2. Methods

2.1. Patients. We enrolled 106 prevalent kidney transplant recipients between November 2005 and October 2009 from the outpatient nephrology clinic at Tufts Medical Center, Boston. Eligible patients were age 18 or older, who were
between 6 months and 5 years posttransplant. Patients who had returned to dialysis, who had systemic illnesses such as an active malignancy, decompensated liver or respiratory disease, AIDS, acute intercurrent illnesses, pregnancy, or multiple organ transplants were excluded. Patients were not eligible for enrollment within 3 months of an acute rejection episode or acute kidney injury of any other cause. All participants provided written informed consent, and the study was approved by the hospital's institutional review board.

2.2. Study Design and Data Collection. Using a cross-sectional study design, we collected demographic, clinical, and laboratory data and medication details from clinically stable kidney transplant patients at the time of enrollment by direct interview and supplemented relevant information from the subject's medical records. Laboratory test results related to mineral metabolism data consisted of measurements of serum calcium, phosphate, and albumin performed at the enrollment visit. Parathyroid hormone measurements were obtained within a 6-month window around the time of enrollment or where unavailable, measured in serum samples collected during the enrollment visit.

2.3. Definitions. CKD was defined as an eGFR of <60 mL/min/1.73 m² and staged per NKF-KDOQI and KDIGO guidelines [5]. eGFR estimation was based on serum creatinine and the Modification of Diet in Renal Disease (MDRD) study equation [6]. An adjustment was made to account for the recalibration of serum creatinine assay performed by our laboratory during the study period. Hypertension was defined as BP >140/90 or the use of antihypertensive medication(s). The presence of cardiovascular disease (CVD) was indicated by the Index of Disease Severity (IDS) scores, a composite score for vascular disease-related variables [7].

Hypophosphatemia was defined as serum phosphate level <2.7 mg/dL. Elevated PTH levels were defined as a measurement >65 pg/mL. Serum calcium was corrected for serum albumin levels [9], and hypercalcemia was defined as a serum calcium level >10.5 mg/dL.

2.4. Sample Collection and Assays. EDTA-anticoagulated blood samples were collected on ice at enrollment and immediately processed for separation of plasma and serum which were aliquoted and stored at −70°C until assay. Plasma levels of intact FGF-23 were measured using Human Intact FGF-23 ELISA kits (Immutopics, San Clemente, CA, USA). The reported assay parameters were sensitivity 1.0 pg/mL, intra-assay coefficient of variation (CV) 4.4% at 14.6 pg/mL and 2.6% at 148 pg/mL, and interassay CV, 6.1% at 15.6 pg/mL and 6.5% at 166 pg/mL. While reference ranges in the general population and clinical utility have not been established [10], previous studies using alternative assays have reported intact FGF-23 levels in healthy controls to range from 8.2 to 54.3 pg/mL and suggest a reference range of 10–50 pg/mL [11–13]. There has been a suggestion that the intact Immunopectins assay may have inferior interassay variability; however, we assayed all samples in duplicate in a single sitting using assay kits from the same batch and therefore do not feel that this issue impacted our results.

2.5. Statistical Analysis. Statistical analysis was performed with the SPSS for Windows 14.0 (SPSS, Chicago, IL, USA). Data were expressed as means and standard deviations for continuous variables that were normally distributed and medians and interquartile ranges for nonnormally distributed data. Log transformation was carried out where appropriate (FGF-23, PTH, and phosphate levels). Categorical data were expressed as proportions. Mineral metabolism parameters were compared across demographic or clinical categories by the t-test or nonparametric tests as applicable. The geometric mean ± sem was computed where log transformation of variables had been performed. Correlations between continuous variables were analyzed using Spearman rank correlation. The determinants of plasma FGF-23 levels were examined using multivariable linear regression; similar analyses were used to compute the contribution of FGF-23 levels to the variability of serum phosphate. Assessment of model fit, residual analysis, and outlier detection were carried out for all regression models. All tests were two tailed, and P values <0.05 were considered significant. All confidence intervals were calculated at the 95% level.

3. Results

3.1. Clinical Characteristics. Table 1 shows the clinical and laboratory characteristics of the study population. The mean ± SD age of the population was 46.8 ± 11.2 years, 62% were male, and 12% were African-American; 55% of the subjects were posttransplant CKD stage 1T and 2T, 45% stage 3T and 4T. Roughly half the patients were between 1 and 5 years from their transplant date. Hypophosphatemia was present in 34% of the patients, hypercalcemia in 3%, and elevated PTH levels in 66%. The prevalence of CVD was 17%, and of documented bone disease was 21%, with radiological evidence of osteoporosis or osteopenia in 19% and avascular necrosis of bone in 2%. The immunosuppressive regimen predominantly consisted of tacrolimus and mycophenolate mofetil; about 45% used steroid-free regimens. Antihypertensive medications were used in 50% of the cohort. Approximately 50% of the study population was receiving treatment with either Calcitriol or Ergocalciferol, and 7% were taking phosphate binders. Males appeared to have significantly higher levels of serum PTH (geometric mean ± sem: 119 ± 1.1 pg/mL versus 83 ± 1.1 pg/mL in females; P = 0.04) and lower levels of serum phosphate than females (geometric mean ± sem: 2.8 ± 0.1 mg/dL versus 3.3 ± 0.1 mg/dL in females, P = 0.002). No significant differences in mineral metabolism parameters were seen by race, presence of diabetes, duration from transplant, presence of CVD, or bone disease.

3.2. Relationship between Mineral Metabolism Parameters and Transplant Kidney Function. eGFR was linearly inversely correlated to both serum calcium and phosphate, patients with higher eGFR having lower levels of both serum calcium
Table 1: Clinical and laboratory characteristics of patient cohort. Both numbers and percentages reported.

| Characteristics                        | Value                  |
|----------------------------------------|------------------------|
| Age (years)                            | 46.9 ± 11.2            |
| Male                                   | 66 (62%)               |
| Caucasian                              | 93 (88%)               |
| Diabetes (pre- or posttransplant)       | 16 (15%)               |
| CKD Stage 1T & 2T                       | 58 (55%)               |
| Stage 3T & 4T                          | 48 (45%)               |
| Cardiovascular disease                  | 18 (17%)               |
| Bone disease                           |                        |
| Osteopenia/osteoporosis                | 20 (19%)               |
| Avascular necrosis                     | 2 (2%)                 |
| Multiple transplants                    | 14 (13%)               |
| Donor source                           |                        |
| Living donor                           | 70 (66%)               |
| Deceased donor                         | 37 (34%)               |
| Preemptive transplantation             | 33 (31%)               |
| Prevalence of delayed graft function   | 16 (15%)               |
| Received induction therapy             | 26 (29%)               |
| Acute rejection episodes               | 15 (14%)               |
| Immunosuppression                      |                        |
| Prednisone                             | 58 (55%)               |
| Tacrolimus                              | 94 (89%)               |
| Mycophenolate Mofetil                  | 86 (81%)               |
| Posttransplant duration (months)*      | 12.8 (7.5–30.9)        |
| eGFR (mL/min/m²)                       | 62.9 ± 21.0            |
| Serum calcium (mg/dL)                  | 9.6 ± 0.5              |
| Serum phosphate                        | 3.1 ± 0.7              |
| Serum PTH levels (pg/mL)*              | 90 (58–172)            |
| Hemoglobin (g/dL)                      | 13.3 ± 1.8             |
| Serum albumin (g/dL)                   | 4.0 ± 0.3              |
| Plasma FGF-23 (pg/mL)*                 | 16 (12–22)             |

and phosphate (Spearman’s rank correlation \( r \), \( P \) value: serum calcium \(-0.27, 0.005\); serum phosphate \(-0.20, 0.04\)).

A higher eGFR was also associated with lower FGF-23 levels (Spearman’s rank correlation \( r \), \( P \) value: \(-0.29, 0.003\); serum PTH and FGF-23 = 0.18, 0.06) and remained significant on adjustment for age, sex, race, transplant kidney function, and each other. The variation of FGF-23 levels with serum-phosphate levels completely explained its variability with transplant kidney function. The effect of phosphate levels on increasing FGF-23 levels appeared to be less marked among patients who had higher PTH and phosphate levels (\( P \) value for interaction 0.02, Figure 1). FGF-23 levels appeared to increase with duration from transplant, the highest levels being seen among patients beyond 2 years from transplant (geometric mean \( ± \) sem 19.9 \( ± \) 1.1 pg/mL beyond 2 years versus 14.1 \( ± \) 1.2 pg/mL less than 2 years from transplant, \( P = 0.02\)). Table 2 shows the independent predictors for FGF-23 levels, the model explaining 22% of the variability of FGF-23 levels in this population.

3.3. Plasma FGF-23 Levels and Its Determinants. Median (25th–75th percentile) FGF-23 levels were 15.8 (12.2–22.5) pg/mL and had a right-skewed distribution. These levels were comparable to levels reported for healthy individuals in earlier studies and were above the reference limit of 50 pg/mL in 7% of patients. FGF-23 levels did not differ by age, sex, race, the presence of diabetes, or duration from transplant but were higher among patients with more advanced transplant CKD (median levels 14.5 pg/mL among patients with CKD stages 1 and 2 and 18.2 pg/mL among patients with CKD stages 3 and 4 (\( P = 0.02\)).

Both higher levels of phosphate and higher PTH levels were associated with higher levels of FGF-23 (Spearman’s rank correlation \( r \), \( P \) value: serum phosphate and FGF-23 = 0.29, 0.003; serum PTH and FGF-23 = 0.18, 0.06) and remained significant on adjustment for age, sex, race, transplant kidney function, and each other. The variation of FGF-23 levels with serum-phosphate levels completely explained its variability with transplant kidney function. The effect of phosphate levels on increasing FGF-23 levels appeared to be less marked among patients who had higher PTH and phosphate levels (\( P \) value for interaction 0.02, Figure 1). FGF-23 levels appeared to increase with duration from transplant, the highest levels being seen among patients beyond 2 years from transplant (geometric mean \( ± \) sem 19.9 \( ± \) 1.1 pg/mL beyond 2 years versus 14.1 \( ± \) 1.2 pg/mL less than 2 years from transplant, \( P = 0.02\)). Table 2 shows the independent predictors for FGF-23 levels, the model explaining 22% of the variability of FGF-23 levels in this population.

3.4. Relative Contributions of FGF-23 and PTH in the Variability of Serum Phosphate. Serum-phosphate levels showed a weak inverse relationship to serum PTH levels (Spearman’s rank correlation \( r \), \( P \) value: \(-0.21, 0.03\)) that disappeared after adjustment for gender, eGFR, and FGF-23 levels. Higher FGF-23 levels remained independently associated with higher serum phosphate levels, explaining 7% of its variability. Table 3 shows the results of multivariable
In contrast to transplant kidney function, the increase in concert with serum phosphate appears to be more marked in patients with impaired initial decrease, FGF-23 level continues to increase, and this change is more marked in patients with impaired transplant kidney function. Indeed, FGF-23 levels appear to increase in concert with serum phosphate, in contrast to the inverse relationship seen early after transplant, and this relationship is independent of transplant kidney function or PTH levels. In our results, PTH also appeared to act as an effect modifier, the presence of elevated levels decreasing the slope of increase in FGF-23 levels with increasing phosphate levels. However, as this study is cross-sectional, we are unable to address temporal relationships; it is neither possible to analyze if increasing levels of serum phosphate, albeit within the normal ranges, in prevalent transplant patients are the primary perturbation leading to FGF-23 elevation, nor if the modulation of this relationship by PTH levels is similar to the pathophysiology of CKD prior to transplantation.

Disordered mineral metabolism, bone disease, and the consequences of vascular calcification persist after transplantation [15, 16]. Patients entering transplantation do so therefore with a significant CVD and risk factor burden with a high likelihood of disease progression [17–19]. Recently, FGF-23 has emerged as a powerful independent predictor of CVD outcomes and mortality in patients with CKD/ESRD [20–22]. Elevations in FGF-23 levels could potentially represent phosphate exposure and mediate its vascular consequences [23]. Furthermore, the adverse consequences of FGF-23 may also be affected through downstream inhibition of Vitamin D hydroxylation [24]. Calcitriol deficiency, observed in up to 45% of transplant patients [25], is associated with myocardial dysfunction, increased vascular calcification [26], as well as increased mortality [27–29]. A recent prospective study suggested that FGF-23 was a risk factor for kidney transplant loss and mortality, and the elevated risk was seen even with minor elevations of FGF-23 levels [30].

Although the present study was cross-sectional at a single center, we obtained valuable insights into mineral metabolism relationships in a prevalent transplant population; moreover, the study population reflected a wide spectrum of transplant kidney function and posttransplant duration increasing the sensitivity to discover relationships and improve its generalizability. However, we acknowledge that our findings should be considered hypothesis generating and preliminary.

We also acknowledge that there is continuing debate regarding the best assay for the measurement of FGF-23 levels [31]. However, there is consensus that there is a good correlation between the different assays [10]. The use of the intact assay in this study was based on its specificity in the setting of decreased GFR where inactive C-terminal fragments could potentially accumulate. Interindividual variability in FGF-23 levels in CKD patients has been reported but in most instances appears to be less marked than the variability of

### Table 2: Multivariable linear regression for FGF-23 levels.

| Variable                                      | β     | 95% CI     | P value |
|-----------------------------------------------|-------|------------|---------|
| Serum phosphate (per log) (mg/dL)             | 4.56  | 1.46       | 7.67    | 0.004  |
| PTH (per log) (pg/mL)                         | 1.03  | 0.30       | 1.76    | 0.006  |
| Serum phosphate (per log) × PTH (per log)     | −0.75 | −1.36      | −0.14   | 0.02   |
| Duration from transplant >2 years (versus ≤2 years) | 0.34  | 0.07       | 0.62    | 0.02   |

Model adjusted for age, sex, race, and eGFR. PTH: parathyroid hormone, CI: confidence interval.

### Table 3: Multivariate linear regression for phosphate levels.

| Variable               | β     | 95% CI     | P value |
|------------------------|-------|------------|---------|
| Sex (female)           | 0.14  | 0.05       | 0.22    | 0.002  |
| eGFR (per 10 mL/min)   | −0.02 | −0.04      | −0.005  | 0.02   |
| PTH (per log) (pg/mL)  | −0.04 | −0.09      | 0.01    | 0.15   |
| FGF-23 (per log) (pg/mL) | 0.08  | 0.02       | 0.15    | 0.01   |

Model adjusted for age, sex, and race. eGFR: estimated glomerular filtration rate, PTH: parathyroid hormone, FGF-23: fibroblast growth factor-23.
other mineral metabolism markers such as serum phosphate or PTH, being in the range of about 10% [32, 33]. Despite these caveats, we found robust trends in the directions of relationships between FGF-23 levels and other mineral metabolism markers in this prevalent transplant population.

In summary, FGF-23 appears to be an important driver of mineral metabolism after transplantation in prevalent transplant patients. Its relationship to serum phosphate differs compared to the early posttransplant period where its phosphaturic effect is more prominent. These results suggest that a phosphatemic stimulus to FGF-23 continues to exist after transplantation and increases in significance after the early posttransplant period especially in the context of impaired transplant kidney function. FGF-23 may play a more important role than PTH in the homeostasis of phosphate, given that the feedback regulation of PTH after transplant is relatively blunted. These changes may have major implications for long-term cardiovascular and graft loss outcomes in this population and highlight the need to study the modulatory role of FGF-23 in mineral metabolism homeostasis in the longer term after transplant.

Acknowledgments

The authors received funding from Grant nos. K23DK 066992 and R56DK84194 (NIH/NIDDK). The authors have declared no conflict of interests.

References

[1] S. M. Sprague, V. Belozeroff, M. D. Danese, L. P. Martin, and K. Olgaard, "Abnormal bone and mineral metabolism in kidney transplant patients—a review," American Journal of Nephrology, vol. 28, no. 2, pp. 246–253, 2008.

[2] I. Bhan, A. Shah, J. Holmes et al., "Post-transplant hypophosphatemia: tertiary “hyper-phosphatonism”?" Kidney International, vol. 70, no. 8, pp. 1486–1494, 2006.

[3] P. Evenepoel, M. Naesens, K. Claes, D. Kuypers, and Y. Vanrenterghem, "Tertiary “hyperphosphatonism” accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients," American Journal of Transplantation, vol. 7, no. 5, pp. 1193–1200, 2007.

[4] A. S. Levey, J. A. Beto, B. E. Coronado et al., "Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here?" American Journal of Kidney Diseases, vol. 32, no. 5, pp. 853–906, 1998.

[5] K. U. Eckardt, J. S. Berns, M. V. Rocco, and B. L. Kasiski, "Definition and classification of CKD: the debate should be about patient prognosis—a position statement from KDQI and KDIGO," American Journal of Kidney Diseases, vol. 53, no. 6, pp. 915–920, 2009.

[6] A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, "A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation," Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999.

[7] D. C. Miskulin, N. V. Athienites, G. Yan et al., "Comorbidity assessment using the index of coexistent diseases in a multicenter clinical trial," Kidney International, vol. 60, no. 4, pp. 1498–1510, 2001.

[8] D. L. Andress, D. W. Coyne, K. Kalantar-Zadeh, M. E. Molitch, F. Zangeneh, and S. M. Sprague, "Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease," Endocrine Practice, vol. 14, no. 1, pp. 18–27, 2008.

[9] C. M. Class, G. L. Norman, M. L. Beecroft, and D. N. Churchill, "Albumin-corrected calcium and ionized calcium in stable haemodialysis patients," Nephrology Dialysis Transplantation, vol. 15, no. 11, pp. 1841–1846, 2000.

[10] M. Wolf, "Forcing forward with 10 burning questions on FGF23 in kidney disease," Journal of the American Society of Nephrology, vol. 21, no. 9, pp. 1427–1435, 2010.

[11] D. Economidou, S. Dovas, A. Papagianni et al., "FGF-23 levels before and after renal transplantation," Journal of Transplantation, vol. 2009, pp. 379–382, 2009.

[12] H. Yamashita, T. Yamashita, M. Miyamoto et al., "Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism," European Journal of Endocrinology, vol. 151, no. 1, pp. 55–60, 2004.

[13] Y. Yamazaki, R. Okazaki, M. Shibata et al., "Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia," Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 11, pp. 4957–4960, 2002.

[14] P. Evenepoel, B. K. I. Meijers, H. de Jong et al., "Recovery of hyperphosphatonism and renal phosphorus wasting one year after successful renal transplantation," Clinical Journal of the American Society of Nephrology, vol. 3, no. 6, pp. 1829–1836, 2008.

[15] S. L. Rosas, K. Mensah, R. B. Weinstein, S. L. Bellamy, and D. J. Rader, "Coronary artery calcification in renal transplant recipients," American Journal of Transplantation, vol. 5, no. 8, pp. 1942–1947, 2005.

[16] K. Schankel, J. Robinson, R. D. Bloom et al., "Determinants of coronary artery calcification progression in renal transplant recipients," American Journal of Transplantation, vol. 7, no. 9, pp. 2158–2164, 2007.

[17] O. M. Gutiérrez, J. L. Januzzi, T. Isakov et al., "Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis," The New England Journal of Medicine, vol. 359, no. 6, pp. 584–592, 2008.

[18] B. D. Parker, L. J. Schurgers, V. M. Brandenburg et al., "The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the heart and soul study," Annals of Internal Medicine, vol. 152, no. 10, pp. 640–648, 2010.

[19] O. M. Gutiérrez, "Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating
the “trade-off” hypothesis,” *Clinical Journal of the American Society of Nephrology*, vol. 5, no. 9, pp. 1710–1716, 2010.

[24] T. Sato, M. Fukagawa, K. Uchida et al., “1,25-dihydroxyvitamin D synthesis after renal transplantation: the role of fibroblast growth factor 23 and cyclosporine,” *Clinical Transplantation*, vol. 23, no. 3, pp. 368–374, 2009.

[25] P. Evenepoel, B. Van Den Bergh, M. Naesens et al., “Calcium metabolism in the early posttransplantation period,” *Clinical Journal of the American Society of Nephrology*, vol. 4, no. 3, pp. 665–672, 2009.

[26] A. Zittermann, S. S. Schleithoff, S. Frisch et al., “Circulating calcitriol concentrations and total mortality,” *Clinical Chemistry*, vol. 55, no. 6, pp. 1163–1170, 2009.

[27] M. Teng, M. Wolf, M. N. Ofsthun et al., “Activated injectable vitamin D and hemodialysis survival: a historical cohort study,” *Journal of the American Society of Nephrology*, vol. 16, no. 4, pp. 1115–1125, 2005.

[28] A. Zittermann, S. S. Schleithoff, C. Götting et al., “Calcitriol deficiency and 1-year mortality in cardiac transplant recipients,” *Transplantation*, vol. 87, no. 1, pp. 118–124, 2009.

[29] K. Falkiewicz, M. Boratynska, B. Speichert-Bidzińska et al., “1,25-dihydroxyvitamin D deficiency predicts poorer outcome after renal transplantation,” *Transplantation Proceedings*, vol. 41, no. 8, pp. 3002–3005, 2009.

[30] M. Wolf, M. Z. Molnar, A. P. Amaral et al., “Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality,” *Journal of the American Society of Nephrology*, vol. 22, no. 5, pp. 956–966, 2011.

[31] X. Barros and J. V. Torregrosa, “Role of FGF23 in kidney transplantation,” *Journal of Transplantation Technology Research*. In press.

[32] T. Isakova, H. Xie, A. Barchi-Chung et al., “Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol,” *Clinical Journal of the American Society of Nephrology*, vol. 7, no. 5, pp. 820–828, 2012.

[33] J. Bacchetta, L. Dubourg, J. Harambat et al., “The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease,” *Journal of Clinical Endocrinology and Metabolism*, vol. 95, no. 4, pp. 1741–1748, 2010.